{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-000693","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2025-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.939488+00:00","generated_at":"2026-05-24T04:56:41.881724+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lipocine initiates Phase 3 outpatient PPD trial of LPCN 1154; dosing expected Q2 2025","bullets":["Initiation of randomized, blinded, placebo-controlled Phase 3 trial of LPCN 1154 for PPD; first patient dosing expected Q2 2025.","48-hour at-home self-administration regimen based on FDA protocol feedback.","Primary endpoint: change from baseline in HAM-D; secondary endpoints include MADRS and HAM-A.","Trial size powered based on observed effect of injectable brexanolone (Zulresso)."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-000693","json":"https://secwatch.observer/filing/0001641172-25-000693.json","markdown":"https://secwatch.observer/filing/0001641172-25-000693.md","text":"https://secwatch.observer/filing/0001641172-25-000693.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000164117225000693/0001641172-25-000693-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000164117225000693/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:56:41.881724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}